Threshold serum concentrations of tumour necrosis factor alpha (TNFα) as a potential marker of the presence of microangiopathy in children and adolescents with type 1 diabetes mellitus (T1DM)

Human Immunology

Volumn 74, Issue 1, 2013, Pages 75-81

  Zorena, Katarzyna ^a   Kula, Marta ^b   Malinowska, Ewa ^b   Raczyńska, Dorota ^b   Myśliwiec, Małgorzata ^b   Raczyńska, Krystyna ^b  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; HEMOGLOBIN A1C; INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN 165;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE MONITORING; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC MICROANGIOPATHY; DISEASE DURATION; EYE EXAMINATION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SCHOOL CHILD; URINARY EXCRETION;

ADOLESCENT; ALBUMINURIA; CASE-CONTROL STUDIES; CHILD; CREATININE; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INTERLEUKIN-12; MALE; PROGNOSIS; RECEPTORS, IMMUNOLOGIC; ROC CURVE; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84870866091     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2012.10.002     Document Type: Article

References (50)

1. Jarosz-Chobot P., Polanska J., Szadkowska A., Kretowski A., Bandurska-Stankiewicz E., Ciechanowska M., et al. Rapid increase in the incidence of type 1 diabetes in Polish children from 1989 to 2004, and predictions for 2010 to 2025. Diabetologia 2011, 54:508-515.
2. Catanzariti L., Faulks K., Moon L., Waters A.M., Flack J., Craig M.E. Australia's national trends in the incidence of Type 1 diabetes in 0-14-year-olds, 2000-2006. Diabet Med 2009, 26:596-601.
3. Patterson C.C., Dahlquist G.G., Gyürüs E., Green A., Soltész G. EURODIAB study group. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009, 373:2027-2030.
4. Cho Y.H., Craig M.E., Hing S., Gallego P.H., Poon M., Chan A., et al. Microvascular complications assessment in adolescents with 2- to 5-yr duration of type 1 diabetes from 1990 to 2006. Pediatr Diabetes 2011, 12:682-689.
5. Kumar P., Krishna P., Reddy S.C., Gurappa M., Aravind S.R., Munichoodappa C. Incidence of type 1 diabetes mellitus and associated complications among children and young adults: results from Karnataka Diabetes Registry 1995-2008. J Indian Med Assoc 2008, 106:708-711.
6. Amin R., Widmer B., Prevost A.T., Schwarze P., Cooper J., Edge J., et al. Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study. BMJ 2008, 336:697-701.
7. Donaghue K.C., Chiarelli F., Trotta D., Allgrove J., Dahl-Jorgensen K. Microvascular and macrovascular complications associated with diabetes in children and adolescents. ISPAD Clinical Practice Consensus Guidelines 2009 Compendium. Pediatr Diabetes 2009, 12:195-203.
8. Mogensen C.E., Keane W.F., Bennett P.H., Jerums G., Parving H.H., Passa P., et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995, 346:1080-1084.
9. Romero P., Salvat M., Fernández J., Baget M., Martinez I. Renal and retinal microangiopathy after 15years of follow-up study in a sample of type 1 diabetes mellitus patients. J Diabetes Complications 2007, 21:93-100.
10. Salardi S., Porta M., Maltoni G., Rubbi F., Rovere S., Cerutti F., et al. Diabetes study group of the Italian society of paediatric endocrinology and diabetology. Infant and toddler type 1 diabetes: complications after 20years' duration. Diabetes Care 2012, 35:829-833.
11. Skrivarhaug T., Bangstad H.J., Stene L.C., Sandvik L., Hanssen K.F., Joner G. Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia 2006, 49:298-305.
12. Gomes MB, de Mattos Matheus AS, Calliari LE, Luescher JL, Manna TD, Savoldelli RD, Cobas RA, Coelho WS, Tschiedel B, Ramos AJ, Fonseca RM, Araujo NB, Almeida HG, Melo NH, Jezini DL, Negrato CA. Economic status and clinical care in young type 1 diabetes patients: a nationwide multicenter study in Brazil. Acta Diabetol 2012 [Epub ahead of print].
13. Govan L., Wu O., Briggs A., Colhoun H.M., McKnight J.A., Morris A.D., et al. Scottish diabetes research network epidemiology group. Inpatient costs for people with type 1 and type 2 diabetes in scotland: a study from the scottish diabetes research network epidemiology group. Diabetologia 2011, 54:2000-2008.
14. Griebsch I., Coast J., Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics 2006, 115:e600-e614.
15. Kawalec P., Pilc A. A cost-effectiveness analysis of treatment of diabetic complications in 2002. J Diabetes Poland 2004, 1:9-14.
16. Cruickshanks K.J., Ritter L.L., Klein R., Moss S.E. The association of microalbuminuria with diabetic retinopathy. The Wisconsin epidemiologic study of diabetic retinopathy. Ophthalmology 1993, 100:862-867.
17. Benitez-Aguirre P.Z., Sasongko M.B., Craig M.E., Jenkins A.J., Cusumano J., Cheung N., et al. Retinal vascular geometry predicts incident renal dysfunction in young people with type 1 diabetes. Diabetes Care 2012, 35:599-604.
18. Berg U.B., Torbjörnsdotter T.B., Jaremko G., Thalme B. Kidney morphological changes in relation to long-term renal function and metabolic control in adolescents with IDDM. Diabetologia 1998, 41(9):1047-1056.
19. Beisswenger P.J., Makita Z., Curphey T.J., Moore L.L., Jean S., Brinck-Johnsen T., et al. Formation of immunochemical advanced glycosylation end-products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995, 44:824-829.
20. Zorena K., Myśliwska J., Myśliwiec M., Balcerska A., Hak Ł., Lipowski P., et al. Serum TNF-alpha level predicts nonproliferative diabetic retinopathy in children. Mediators Inflamm 2007, http://dx.doi.org/10.1155/2007/92196.
21. Myśliwiec M., Balcerska A., Zorena K., Myśliwska J., Lipowski P., Raczyńska K. The role of vascular endothelial growth factor, tumor necrosis factor alpha and interleukin-6 in pathogenesis of diabetic retinopathy. Diabetes Res Clin Pract 2008, 79:141-146.
22. Zorena K., Myśliwska J., Myśliwiec M., Balcerska A., Lipowski P., Raczyńska K. Interleukin-12 and tumour necrosis factor-alpha equilibrium is a prerequisite for clinical course free from late complications in children with type 1 diabetes mellitus. Scand J Immunol 2008, 67:204-208.
23. Sheetz M.J., King G.L. Molecular understanding of hyperglycemiás adverse effects for diabetic complications. JAMA 2002, 288:2579-2588.
24. Rojas A., Morales M.A. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes. Life Sci 2004, 76:715-730.
25. DAgati V, Yan SF, Ramasamy R, Schmidt AM. RAGE, glomerulosclerosis and proteinuria: roles in podocytes and endothelial cells, Trends Endocrinol Metab 2010;21:50-56.
26. Katakami N., Matsuhisa M., Kaneto H., Matsuoka T., Sakamoto K., Yasuda T. Endogenous secretory RAGE but not soluble RAGE is associated with caroid atherosclerosis in type 1 diabetes patients, Daibetes Vasc. Dis Res 2001, 5:190-197.
27. Bucciarelle L.G., Wendt T., Qu W., Lu Y., Lalla E., Rong L.L., et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Criculation 2002, 106:2827-2835.
28. Chiarelli F., Catino M., Tumini S., Cipollone F., Mezzetti A., Vanelli M., et al. Advanced glycation end products in adolescents and young adults with diabetic angiopathy. Pediatr Nephrol 2000, 14:841-846.
29. Galler A., Müller G., Schinzel R., Kratzsch J., Kiess W., Münch G. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and epsilon-(carboxymethyl)lysine. Diabetes Care 2003, 26:2609-2615.
30. Kostolanská J., Jakus V., Barák L. HbA1c and serum levels of advanced glycation and oxidation protein products in poorly and well controlled children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2009, 22:433-442.
31. American Diabetes Association Diagnosis and classification of diabetes. Diabetes Care 2010, 33:62-69.
32. Position of the Polish Diabetes Association Clinical recommendations for treatment of patients with diabetes. J Diabetes Poland 2011, 12(1):A3-A7.
33. ETDRS Rerearch Group, ETDRS Report No. 11. Classification of diabetic retinopathy from fluorescein angiograms. Ophthalmology 1991;98:807-822.
34. 24th Report. The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescent. Pediatrics 2004;114:555-576.
35. Hanley J.A., McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143:29-36.
36. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a non-parametric approach. Biometrics 1988, 44:837-842.
37. Dettoraki A., Rojas Gil A.P., Spiliotis B.E. Association between serum levels of the soluble receptor (sRAGE) for advanced glycation endproducts (AGEs) and their receptor (RAGE) in peripheral blood mononuclear cells of children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2009, 22:895-904.
38. Wirostko B., Wong T.Y., Simó R. Vascular endothelial growth factor and diabetic complications. Prog Retin Eye Res 2008, 27:608-621.
39. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:667-669.
40. Chiarelli F., Spagnoli A., Basciani F., Tumini S., Mezzetti A., Cipollone F., et al. Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with type 1 diabetes mellitus: relation to glycaemic control and microvascular complications. Diabet Med 2000, 17:650-656.
41. Zorena K., Myśliwska J., Myśliwiec M., Balcerska A., Lipowski P., Raczyńska D., et al. Modulatory factors responsible for neoangiogenesis in young patients with long-standing diabetes mellitus type 1. Recent. Patents Endocr Metabol Immun Drug Disc 2009, 3:144-149.
42. Santilli F., Spagnoli A., Mohn A., Tumini S., Verrotti A., Cipollone F., et al. Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type 1 diabetes during childhood at risk for developing persistent microalbuminuria. J Clin Endocrinol Metab 2001, 86:3871-3876.
43. Zhu H., Shi C.H. Changes of plasma endothelin-1 and vascular endothelial growth factor in diabetic retinopathy and the clinical application value thereof. Zhonghua Yi Xue Za Zhi 2007, 87:2837-2839.
44. Zamora C.R., Cubeddu L.X. Microalbuminuria: do we need a new threshold?. J Hum Hypertens 2009, 23:146-149.
45. Donaghue K.C., Craig M.E., Chan A.K., Fairchild J.M., Cusumano J.M., Verge C.F., et al. Prevalence of diabetes complications 6years after diagnosis in an incident cohort of childhood diabetes. Diabet Med 2009, 22:711-718.
46. Krasny J., Andel M., Brunnerova R., Cihelkova I., Dominek Z., Lebl J., et al. The contrast sensitivity test in early detection of ocular changes in the relation to the type I diabetes mellitus compensation in children, teenagers, and young adults. Recent Pat Inflamm Allergy Drug Discov 2007, 1:232-236.
47. Klein R., Klein B.E., Moss S.E., Davis M.D., DeMets D.L. The Wisconsin epidemiologic study of diabetic retinopathy. IX Four-year incidence and progression of diabetic retinopathy when age at diagnosis is <30years. Arch Ophtalmol 1989, 107:237-243.
48. Twyman S., Rowe D., Mansell P., Schapira D., Betts P., Leatherdale B. Wessex Diabetic Nephropathy Project Longitudinal study of urinary albumin excretion in young diabetic patients - Wessex Diabetic. Nephropathy Project. Diabet. Med. 2001, 18:402-408.
49. Rossing P., Hougaard P., Parving H.H. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care 2002, 25:859-864.
50. Gurrola-Díaz C.M., Sánchez-Enriquez S., Oregon-Romero E., García-López P.M., Garzón de la Mora P., Bastidas-Ramírez B.E., et al. Establishment of a cut-point value of serum TNF-alpha levels in the metabolic syndrome. J Clin Lab Anal. 2009, 23:51-56.